Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
SanBio Co ( (JP:4592) ) has provided an announcement.
SanBio Co., Ltd. announced a revision in the expected approval timing for partial changes to its product, AKUUGO® Suspension for Intracranial Implantation. The company has completed the filing for a partial change application and anticipates regulatory approval in the second half of the fiscal year ending January 2026. The launch of AKUUGO® is planned following reimbursement pricing approval, with minimal impact expected on the current fiscal year’s financial performance.
The most recent analyst rating on (JP:4592) stock is a Hold with a Yen1400.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd. is a company engaged in the regenerative cell business, focusing on research, development, manufacturing, and sales of regenerative cell medicines. Founded in California in 2001, the company aims to be a global leader in regenerative medicine, particularly targeting central nervous system disorders with unmet medical needs. SanBio is headquartered in Tokyo, Japan.
Average Trading Volume: 5,665,654
Technical Sentiment Signal: Buy
Current Market Cap: Yen203.1B
Learn more about 4592 stock on TipRanks’ Stock Analysis page.